4.1 Article

Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions

Journal

BIOPHARMACEUTICS & DRUG DISPOSITION
Volume 32, Issue 3, Pages 175-184

Publisher

WILEY-BLACKWELL
DOI: 10.1002/bdd.749

Keywords

transporter-mediated drug-drug interaction; ketoconazole; rifampin; olmesartan; OAT1; OATP1B1

Funding

  1. Center for Biological Modulators [CBM34-B4000-01-01-00]
  2. National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology [2010-0005370]
  3. National Research Foundation of Korea [2010-0005370] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Ketoconazole and rifampin are the most widely used compounds examined in recent drug-drug interaction (DDI) studies, and they have multiple roles in modulating drug metabolizing enzymes and transporters. To determine the underlying mechanisms of DDI, this study was performed to investigate the inhibitory effects of ketoconazole and rifampin on the functions of OAT1 and OATP1B1, and to evaluate the potential of ketoconazole and rifampin for DDI with substrate drugs for these transporters in a clinical setting. Ketoconazole inhibited OATP1B1-mediated transport activity, while rifampin inhibited OAT1 and OATP1B1. Inhibition by rifampin and ketoconazole of the uptake of olmesartan, a substrate for OAT1 and OATP1B1, was evaluated in oocytes overexpressing these transporters. The K(i) values for rifampin on OAT1 and OATP1B1-mediated olmesartan uptake were 62.2 and 4.42 mu M, respectively, and the K(i) value for ketoconazole on OATP1B1-mediated olmesartan uptake was 66.1 mu M. As measured plasma concentrations of rifampin and ketoconazole were 7.29 and 6.4-13.3 mu M, respectively, the likelihood of an OATP1B1-mediated drug-drug interaction between rifampin and olmesartan is thought to be possible, whereas OAT1 or OATP1B1-mediated DDI between rifampin or ketoconazole and olmesartan appears unlikely in the clinical setting. Copyright (C) 2011 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available